DK3085783T3 - Bispecifikt antistof som substitution for funktionelle proteiner - Google Patents

Bispecifikt antistof som substitution for funktionelle proteiner Download PDF

Info

Publication number: DK3085783T3
Authority: DK; Denmark
Prior art keywords: substitution; blood coagulation; bispecific antibody; coagulation factor; functional proteins
Prior art date: 2003-10-10

Application number

DK16162353.3T

Other languages

English (en)

Inventor

Kunihiro Hattori

Tetsuo Kojima

Taro Miyazaki

Tetsuhiro Soeda

Original Assignee

Chugai Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-10

Filing date

2004-10-08

Publication date

2021-04-26

2003-10-14 Priority claimed from PCT/JP2003/013123 external-priority patent/WO2005035754A1/ja

2004-10-08 Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd

2021-04-26 Application granted granted Critical

2021-04-26 Publication of DK3085783T3 publication Critical patent/DK3085783T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Diabetes (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)

DK16162353.3T 2003-10-10 2004-10-08 Bispecifikt antistof som substitution for funktionelle proteiner DK3085783T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
PCT/JP2003/013062 WO2005035753A1 (ja)	2003-10-10	2003-10-10	機能蛋白質を代替する二重特異性抗体
PCT/JP2003/013123 WO2005035754A1 (ja)	2003-10-14	2003-10-14	機能蛋白質を代替する二重特異性抗体
EP10180356A EP2289944A3 (en)	2003-10-10	2004-10-08	Bispecific antibody substituting for functional proteins

Publications (1)

Publication Number	Publication Date
DK3085783T3 true DK3085783T3 (da)	2021-04-26

Family

ID=34430861

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK04792180.4T DK1688488T3 (da)	2003-10-10	2004-10-08	Bispecifikt antistof som erstatning for faktor III
DK16162353.3T DK3085783T3 (da)	2003-10-10	2004-10-08	Bispecifikt antistof som substitution for funktionelle proteiner

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK04792180.4T DK1688488T3 (da)	2003-10-10	2004-10-08	Bispecifikt antistof som erstatning for faktor III

Country Status (20)

Country	Link
US (1)	US8062635B2 (da)
EP (3)	EP1688488B9 (da)
KR (2)	KR101361437B1 (da)
CN (1)	CN1890369B (da)
AT (1)	ATE518952T1 (da)
AU (2)	AU2003271174A1 (da)
BR (1)	BRPI0415230B1 (da)
CA (1)	CA2541671C (da)
DK (2)	DK1688488T3 (da)
ES (1)	ES2370250T3 (da)
IL (1)	IL174794A (da)
MX (1)	MXPA06003831A (da)
NO (2)	NO345624B1 (da)
NZ (1)	NZ546509A (da)
PL (1)	PL3085783T3 (da)
RU (1)	RU2339696C2 (da)
SI (1)	SI3085783T1 (da)
TW (1)	TW200514790A (da)
UA (1)	UA95438C2 (da)
WO (2)	WO2005035753A1 (da)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
GB0300571D0 (en) *	2003-01-10	2003-02-12	Imp College Innovations Ltd	Modification of feeding behaviour
WO2004111233A1 (ja) *	2003-06-11	2004-12-23	Chugai Seiyaku Kabushiki Kaisha	抗体の製造方法
AU2003271174A1 (en)	2003-10-10	2005-04-27	Chugai Seiyaku Kabushiki Kaisha	Double specific antibodies substituting for functional protein
EP1693448A4 (en) *	2003-10-14	2008-03-05	Chugai Pharmaceutical Co Ltd	DOUBLE SPECIFIC ANTIBODIES AS REPLACEMENT FOR FUNCTIONAL PROTEIN
US8187595B2 (en)	2004-05-07	2012-05-29	The University Of North Carolina At Chapel Hill	Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
CN101027391A (zh) *	2004-10-05	2007-08-29	惠氏公司	用于改善重组蛋白质产生的方法和组合物
US8916165B2 (en)	2004-12-15	2014-12-23	Janssen Alzheimer Immunotherapy	Humanized Aβ antibodies for use in improving cognition
TWI671403B (zh)	2005-03-31	2019-09-11	中外製藥股份有限公司	控制組裝之多肽的製造方法
TW200714313A (en) *	2005-04-08	2007-04-16	Chugai Pharmaceutical Co Ltd	Antibodies that substitute for coagulation factor VIII
DK2009101T3 (da)	2006-03-31	2018-01-15	Chugai Pharmaceutical Co Ltd	Antistofmodifikationsfremgangsmåde til oprensning af et bispecifikt antistof
DK3056568T3 (da)	2006-03-31	2021-11-01	Chugai Pharmaceutical Co Ltd	Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
JP2009274958A (ja) *	2006-08-31	2009-11-26	Nara Prefecture	血液凝固第ｖｉｉｉ因子の活性化を促進する抗体
US9624309B2 (en)	2007-08-15	2017-04-18	Bayer Intellectual Property Gmbh	Monospecific and multispecific antibodies and method of use
EP3689912A1 (en)	2007-09-26	2020-08-05	Chugai Seiyaku Kabushiki Kaisha	Method of modifying isoelectric point of antibody via amino acid substitution in cdr
KR102467302B1 (ko)	2007-09-26	2022-11-14	추가이 세이야쿠 가부시키가이샤	항체 정상영역 개변체
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
KR101840994B1 (ko) *	2007-12-05	2018-03-21	추가이 세이야쿠 가부시키가이샤	항ｎｒ１０ 항체 및 그의 이용
KR102057826B1 (ko)	2008-04-11	2019-12-20	추가이 세이야쿠 가부시키가이샤	복수 분자의 항원에 반복 결합하는 항원 결합 분자
CA2733497C (en) *	2008-08-06	2015-06-02	Eli Lilly And Company	Anti-hepcidin-25 selective antibodies and uses thereof
TWI440469B (zh)	2008-09-26	2014-06-11	Chugai Pharmaceutical Co Ltd	Improved antibody molecules
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
AU2009335798B2 (en) *	2008-12-19	2014-11-27	Macrogenics, Inc.	Covalent diabodies and uses thereof
EP3674317B1 (en)	2009-03-19	2024-12-11	Chugai Seiyaku Kabushiki Kaisha	Antibody constant region variant
US9228017B2 (en)	2009-03-19	2016-01-05	Chugai Seiyaku Kabushiki Kaisha	Antibody constant region variant
TW201041595A (en)	2009-05-15	2010-12-01	Chugai Pharmaceutical Co Ltd	Anti-axl antibody
RU2595409C2 (ru)	2009-09-03	2016-08-27	Мерк Шарп И Доум Корп.,	Анти-gitr-антитела
US10150808B2 (en)	2009-09-24	2018-12-11	Chugai Seiyaku Kabushiki Kaisha	Modified antibody constant regions
TWI609698B (zh)	2010-01-20	2018-01-01	中外製藥股份有限公司	穩定化的含抗體溶液製劑
JP5889181B2 (ja)	2010-03-04	2016-03-22	中外製薬株式会社	抗体定常領域改変体
AR081434A1 (es)	2010-06-10	2012-08-29	Lilly Co Eli	Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
CA2817964C (en)	2010-11-17	2018-06-12	Chugai Seiyaku Kabushiki Kaisha	Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
TWI761912B (zh)	2010-11-30	2022-04-21	日商中外製藥股份有限公司	具有鈣依存性的抗原結合能力之抗體
WO2012085069A2 (en) *	2010-12-23	2012-06-28	Roche Diagnostics Gmbh	Detection of a polypeptide dimer by a bivalent binding agent
CN103384681B (zh)	2010-12-23	2018-05-18	霍夫曼-拉罗奇有限公司	结合剂
WO2012085064A1 (en)	2010-12-23	2012-06-28	Roche Diagnostics Gmbh	Detection of a posttranslationally modified polypeptide by a bi-valent binding agent
SG191153A1 (en)	2010-12-23	2013-07-31	Hoffmann La Roche	Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
WO2012093704A1 (ja)	2011-01-07	2012-07-12	中外製薬株式会社	抗体の物性を改善させる方法
SG192945A1 (en)	2011-02-25	2013-09-30	Chugai Pharmaceutical Co Ltd	Fcgriib-specific fc antibody
TW201817744A (zh)	2011-09-30	2018-05-16	日商中外製藥股份有限公司	具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
JP6322411B2 (ja)	2011-09-30	2018-05-09	中外製薬株式会社	複数の生理活性を有する抗原の消失を促進する抗原結合分子
JP6371059B2 (ja)	2011-10-31	2018-08-08	中外製薬株式会社	重鎖と軽鎖の会合が制御された抗原結合分子
AU2013205658B2 (en) *	2012-02-29	2015-04-16	Otsuka Pharmaceutical Co., Ltd.	Anti - Lipoarabinomannan antibody and immunoassay for acid - fast bacillary infection using the antibody
EA036225B1 (ru)	2012-03-14	2020-10-15	Ридженерон Фармасьютикалз, Инк.	Мультиспецифические антигенсвязывающие молекулы и их применения
AU2013306390B2 (en)	2012-08-24	2018-07-05	The Regents Of The University Of California	Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
KR20150047602A (ko)	2012-08-31	2015-05-04	더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐	인슐린 유사 성장 인자 1(igf-1)을 증강 또는 억제시키는 모노클로날 항체
TWI609083B (zh) *	2012-09-28	2017-12-21	Chugai Pharmaceutical Co Ltd	Blood coagulation reaction assessment method
EP3050896B1 (en)	2013-09-27	2021-07-07	Chugai Seiyaku Kabushiki Kaisha	Method for producing polypeptide heteromultimer
US10035847B2 (en)	2013-10-02	2018-07-31	The Rockefeller University	Amyloid protofibril antibodies and methods of use thereof
TWI831106B (zh)	2014-06-20	2024-02-01	日商中外製藥股份有限公司	用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
GB201412658D0 (en)	2014-07-16	2014-08-27	Ucb Biopharma Sprl	Molecules
TWI700300B (zh)	2014-09-26	2020-08-01	日商中外製藥股份有限公司	中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
TWI701435B (zh)	2014-09-26	2020-08-11	日商中外製藥股份有限公司	測定ｆｖｉｉｉ的反應性之方法
MA40764A (fr)	2014-09-26	2017-08-01	Chugai Pharmaceutical Co Ltd	Agent thérapeutique induisant une cytotoxicité
EP4600372A3 (en)	2014-12-19	2025-11-19	Chugai Seiyaku Kabushiki Kaisha	Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
BR112017011235A2 (pt)	2014-12-19	2018-02-06	Chugai Pharmaceutical Co Ltd	anticorpos anti-c5 e métodos de uso
CN114773469B (zh)	2015-02-05	2025-12-19	中外制药株式会社	包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
TWI805046B (zh)	2015-02-27	2023-06-11	日商中外製藥股份有限公司	Il-6受體抗體用於製備醫藥組成物的用途
EP3279216A4 (en)	2015-04-01	2019-06-19	Chugai Seiyaku Kabushiki Kaisha	PROCESS FOR PREPARING POLYPEPTIDE HETERO OLIGOMER
CN107454906B (zh) *	2015-04-17	2022-05-27	豪夫迈·罗氏有限公司	使用凝固因子和多特异性抗体的联合治疗
JP2018123055A (ja) *	2015-04-24	2018-08-09	公立大学法人奈良県立医科大学	血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｘｉ因子（ｆｘｉ）異常症の予防および／または治療に用いられる医薬組成物
FR3038517B1 (fr)	2015-07-06	2020-02-28	Laboratoire Francais Du Fractionnement Et Des Biotechnologies	Utilisation de fragments fc modifies en immunotherapie
KR20180025865A (ko)	2015-07-06	2018-03-09	리제너론 파마슈티칼스 인코포레이티드	다중특이적 항원 결합 분자 및 이의 용도
GB201601073D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibodies
GB201601077D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibody molecule
CA2993423C (en)	2015-09-18	2024-03-12	Chugai Seiyaku Kabushiki Kaisha	Il-8-binding antibodies and uses thereof
GB201521382D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Antibodies
WO2017110981A1 (en)	2015-12-25	2017-06-29	Chugai Seiyaku Kabushiki Kaisha	Anti-myostatin antibodies and methods of use
JP6954842B2 (ja)	2015-12-25	2021-10-27	中外製薬株式会社	増強された活性を有する抗体及びその改変方法
BR112018009312A8 (pt)	2015-12-28	2019-02-26	Chugai Pharmaceutical Co Ltd	método para promover eficiência de purificação de polipeptídeo contendo região de fc
KR102185867B1 (ko)	2016-02-06	2020-12-02	에피맙 바이오테라퓨틱스 인코포레이티드	Fabs-인-탠덤 면역글로불린 및 이의 용도
BR112018068363A2 (pt)	2016-03-14	2019-01-15	Chugai Seiyaku Kabushiki Kaisha	fármaco terapêutico indutor de dano celular para uso em terapia de câncer
EP3448891A1 (en)	2016-04-28	2019-03-06	Regeneron Pharmaceuticals, Inc.	Methods of making multispecific antigen-binding molecules
MX2018012648A (es)	2016-04-28	2019-01-30	Chugai Pharmaceutical Co Ltd	Preparaciones que contienen anticuerpos.
CN109996544A (zh)	2016-06-27	2019-07-09	加利福尼亚大学董事会	癌症治疗组合
BR112019001179A2 (pt)	2016-07-29	2019-04-30	Chugai Seiyaku Kabushiki Kaisha	anticorpo biespecífico que exibe atividade alternativa aumentada de função de cofator fviii
KR102102734B1 (ko)	2016-08-05	2020-04-22	추가이 세이야쿠 가부시키가이샤	Il-8 관련 질환의 치료용 또는 예방용 조성물
WO2018047813A1 (en)	2016-09-06	2018-03-15	Chugai Seiyaku Kabushiki Kaisha	Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
US20230192896A1 (en)	2016-11-23	2023-06-22	Bioverativ Therapeutics Inc.	Bispecific antibodies binding to coagulation factor ix and coagulation factor x
US12084512B2 (en)	2017-02-01	2024-09-10	Novo Nordisk A/S	Procoagulant antibodies
WO2018181870A1 (ja)	2017-03-31	2018-10-04	公立大学法人奈良県立医科大学	血液凝固第ｖｉｉｉ因子の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｉｘ因子異常症の予防および／または治療に用いられる医薬組成物
US11851486B2 (en)	2017-05-02	2023-12-26	National Center Of Neurology And Psychiatry	Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
CN110809583A (zh)	2017-06-07	2020-02-18	瑞泽恩制药公司	用于内化酶的组合物和方法
GB201709970D0 (en) *	2017-06-22	2017-08-09	Kymab Ltd	Bispecific antigen-binding molecules
UA128389C2 (uk)	2017-09-29	2024-07-03	Чугаі Сейяку Кабусікі Кайся	Мультиспецифічна антигензв'язувальна молекула, яка має активність заміщувати кофакторну функцію фактора коагуляції крові viii (fviii), та фармацевтичний склад, який містить згадану молекулу як активний інгредієнт
MX2020003472A (es)	2017-11-01	2020-08-03	Chugai Pharmaceutical Co Ltd	Variante e isoforma de anticuerpos con actividad biologica reducida.
MA50893A (fr)	2017-11-15	2020-09-23	Novo Nordisk As	Liants de facteur x renforçant l'activation fx
JP7328990B2 (ja)	2018-04-30	2023-08-17	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	Ｈｅｒ２及び／またはａｐｌｐ２に結合する抗体及び二重特異性抗原結合分子、ならびにそれらのコンジュゲート及び使用
CN112074541A (zh)	2018-05-03	2020-12-11	上海岸迈生物科技有限公司	Pd-1和lag-3的高亲和力抗体以及由其制备的双特异性结合蛋白
CA3100021A1 (en)	2018-05-17	2019-11-21	Regeneron Pharmaceuticals, Inc.	Anti-cd63 antibodies, conjugates, and uses thereof
WO2019235420A1 (ja)	2018-06-04	2019-12-12	中外製薬株式会社	複合体を検出する方法
FR3082427B1 (fr)	2018-06-14	2020-09-25	Lab Francais Du Fractionnement	Combinaison de facteur vii et d'un anticorps bispecifique anti-facteurs ix et x
SG11202100418PA (en) *	2018-08-01	2021-02-25	Novo Nordisk As	Improved procoagulant antibodies
US11220554B2 (en)	2018-09-07	2022-01-11	Novo Nordisk A/S	Procoagulant antibodies
WO2020056334A1 (en) *	2018-09-14	2020-03-19	University Of New England	Methods and diagnostics for cancer detection and treatment monitoring
US10815308B2 (en)	2018-12-21	2020-10-27	Kymab Limited	FIXaxFX bispecific antibody with common light chain
PE20212262A1 (es) *	2019-04-17	2021-11-29	Novo Nordisk As	Anticuerpos biespecificos
EP3969481A1 (en) *	2019-05-15	2022-03-23	Kymab Limited	Improved lambda antibodies
WO2021070885A1 (ja)	2019-10-11	2021-04-15	中外製薬株式会社	後天性血友病ａの予防および／または治療に用いられる医薬組成物、および当該医薬組成物を含む製品
US20220305122A1 (en)	2019-10-11	2022-09-29	Chugai Seiyaku Kabushiki Kaisha	Pharmaceutical composition which can be used for prevention and/or treatment of acquired hemophilia a, and product comprising said pharmaceutical composition
EP4081539A4 (en) *	2019-12-24	2024-02-21	Dizal (Jiangsu) Pharmaceutical Co., Ltd.	Novel anti-fgfr2b antibodies
JP2023106635A (ja)	2020-04-17	2023-08-02	中外製薬株式会社	二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
WO2021235537A1 (ja)	2020-05-22	2021-11-25	中外製薬株式会社	凝固第ｖｉｉｉ因子（ｆ．ｖｉｉｉ）機能代替活性を有する物質を中和する抗体
CN112794903B (zh) *	2021-04-14	2021-06-25	广州市雷德生物科技有限公司	一种特异性结合IFN-γ的抗体及其应用
US20250066436A1 (en)	2021-12-22	2025-02-27	Royal College Of Surgeons In Ireland	A conjugate for use in localising a molecule to the vascular endothelium
WO2025076507A1 (en) *	2023-10-06	2025-04-10	The Children's Hospital Of Philadelphia	Engineered proteins and methods of use thereof
GB202316779D0 (en) *	2023-11-01	2023-12-13	Ucl Business Ltd	Antigen binding protein

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4208479A (en) *	1977-07-14	1980-06-17	Syva Company	Label modified immunoassays
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
US4474893A (en)	1981-07-01	1984-10-02	The University of Texas System Cancer Center	Recombinant monoclonal antibodies
US4444878A (en) *	1981-12-21	1984-04-24	Boston Biomedical Research Institute, Inc.	Bispecific antibody determinants
HUT35524A (en)	1983-08-02	1985-07-29	Hoechst Ag	Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4945050A (en)	1984-11-13	1990-07-31	Cornell Research Foundation, Inc.	Method for transporting substances into living cells and tissues and apparatus therefor
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US6010902A (en) *	1988-04-04	2000-01-04	Bristol-Meyers Squibb Company	Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
IL89491A0 (en)	1988-11-17	1989-09-10	Hybritech Inc	Bifunctional chimeric antibodies
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE68928946T2 (de) *	1989-12-11	1999-10-21	Immunomedics, Inc.	Verfahren zum aufspüren von diagnostischen oder therapeutischen mitteln durch antikörper
TW212184B (da) *	1990-04-02	1993-09-01	Takeda Pharm Industry Co Ltd
JPH05184383A (ja)	1990-06-19	1993-07-27	Dainabotsuto Kk	二重特異性抗体
JPH05199894A (ja)	1990-08-20	1993-08-10	Takeda Chem Ind Ltd	二重特異性抗体および抗体含有薬剤
DE69127627T2 (de)	1990-08-29	1998-02-19	Genpharm Int	Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
JPH05304992A (ja)	1991-06-20	1993-11-19	Takeda Chem Ind Ltd	ハイブリッド・モノクローナル抗体および抗体含有薬剤
WO1993011161A1 (en)	1991-11-25	1993-06-10	Enzon, Inc.	Multivalent antigen-binding proteins
CA2124967C (en)	1991-12-17	2008-04-08	Nils Lonberg	Transgenic non-human animals capable of producing heterologous antibodies
JPH05203652A (ja)	1992-01-28	1993-08-10	Fuji Photo Film Co Ltd	抗体酵素免疫分析法
JPH05213775A (ja)	1992-02-05	1993-08-24	Otsuka Pharmaceut Co Ltd	Ｂｆａ抗体
ES2242954T3 (es)	1992-03-11	2005-11-16	Powderject Vaccines, Inc.	Vacuna genetica para el virus de la inmunodeficiencia.
US6129914A (en)	1992-03-27	2000-10-10	Protein Design Labs, Inc.	Bispecific antibody effective to treat B-cell lymphoma and cell line
US5744446A (en) *	1992-04-07	1998-04-28	Emory University	Hybrid human/animal factor VIII
EP0652950B1 (en)	1992-07-24	2007-12-19	Amgen Fremont Inc.	Generation of xenogeneic antibodies
EP0754225A4 (en)	1993-04-26	2001-01-31	Genpharm Int	HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS
US5945311A (en) *	1994-06-03	1999-08-31	GSF--Forschungszentrumfur Umweltund Gesundheit	Method for producing heterologous bi-specific antibodies
DE122009000068I2 (de)	1994-06-03	2011-06-16	Ascenion Gmbh	Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
DE69519929T2 (de)	1994-07-11	2001-05-23	Board Of Regents, The University Of Texas System	Verfahren und zusammensetzungen für die spezifische koagulation von tumorgefässen
HU221385B1 (en)	1994-07-13	2002-09-28	Chugai Pharmaceutical Co Ltd	Reconstituted human antibody against human interleukin-8
CA2207869A1 (en)	1994-12-02	1996-06-06	Chiron Corporation	Method of promoting an immune response with a bispecific antibody
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
KR100654645B1 (ko)	1995-04-27	2007-04-04	아브게닉스, 인크.	면역화된 제노마우스 유래의 인간 항체
AU2466895A (en)	1995-04-28	1996-11-18	Abgenix, Inc.	Human antibodies derived from immunized xenomice
MA24512A1 (fr) *	1996-01-17	1998-12-31	Univ Vermont And State Agrienl	Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
WO1998003546A1 (en)	1996-07-19	1998-01-29	Amgen Inc.	Analogs of cationic proteins
JPH10165184A (ja)	1996-12-16	1998-06-23	Tosoh Corp	抗体、遺伝子及びキメラ抗体の製法
US20030207346A1 (en) *	1997-05-02	2003-11-06	William R. Arathoon	Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) *	1997-05-02	2002-05-23	Genentech, Inc.	Method for making multispecific antibodies having heteromultimeric and common components
ATE299938T1 (de)	1997-05-02	2005-08-15	Genentech Inc	Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
DE19725586C2 (de) *	1997-06-17	1999-06-24	Gsf Forschungszentrum Umwelt	Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper
US6207805B1 (en)	1997-07-18	2001-03-27	University Of Iowa Research Foundation	Prostate cell surface antigen-specific antibodies
US6342220B1 (en)	1997-08-25	2002-01-29	Genentech, Inc.	Agonist antibodies
CA2325346A1 (en)	1998-04-03	1999-10-14	Chugai Seiyaku Kabushiki Kaisha	Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody
WO2000009560A2 (en)	1998-08-17	2000-02-24	Abgenix, Inc.	Generation of modified molecules with increased serum half-lives
AT411997B (de)	1999-09-14	2004-08-26	Baxter Ag	Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
JP2002112369A (ja)	2000-10-03	2002-04-12	Sharp Corp	端末網制御装置
US20030008880A1 (en)	2001-05-02	2003-01-09	Pfizer Inc.	4-(2-Pyridyl) piperizines having 5HT7 receptor agonist activity
CA2463879C (en)	2001-10-25	2012-12-04	Genentech, Inc.	Glycoprotein compositions
DE10156482A1 (de) *	2001-11-12	2003-05-28	Gundram Jung	Bispezifisches Antikörper-Molekül
EP1500665B1 (en) *	2002-04-15	2011-06-15	Chugai Seiyaku Kabushiki Kaisha	METHODS FOR CONSTRUCTING scDb LIBRARIES
AU2003235833A1 (en)	2002-04-26	2003-11-10	Chugai Seiyaku Kabushiki Kaisha	Method of screening agonistic antibody
US20050130224A1 (en)	2002-05-31	2005-06-16	Celestar Lexico- Sciences, Inc.	Interaction predicting device
ATE431423T1 (de)	2003-01-21	2009-05-15	Chugai Pharmaceutical Co Ltd	Verfahren zum screening der leichten kette eines antikörpers
AU2003271174A1 (en)	2003-10-10	2005-04-27	Chugai Seiyaku Kabushiki Kaisha	Double specific antibodies substituting for functional protein
EP1693448A4 (en)	2003-10-14	2008-03-05	Chugai Pharmaceutical Co Ltd	DOUBLE SPECIFIC ANTIBODIES AS REPLACEMENT FOR FUNCTIONAL PROTEIN
TWI671403B (zh)	2005-03-31	2019-09-11	中外製藥股份有限公司	控制組裝之多肽的製造方法
EP1870458B1 (en)	2005-03-31	2018-05-09	Chugai Seiyaku Kabushiki Kaisha	sc(Fv)2 STRUCTURAL ISOMERS
TW200714313A (en) *	2005-04-08	2007-04-16	Chugai Pharmaceutical Co Ltd	Antibodies that substitute for coagulation factor VIII
CA2610987C (en) *	2005-06-10	2013-09-10	Chugai Seiyaku Kabushiki Kaisha	Stabilizer for protein preparation comprising meglumine and use thereof
DK3056568T3 (da) *	2006-03-31	2021-11-01	Chugai Pharmaceutical Co Ltd	Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
DK2009101T3 (da)	2006-03-31	2018-01-15	Chugai Pharmaceutical Co Ltd	Antistofmodifikationsfremgangsmåde til oprensning af et bispecifikt antistof
RU2511406C2 (ru)	2006-06-08	2014-04-10	Чугаи Сейяку Кабусики Кайся	Профилактическое или лекарственное средство для воспалительного заболевания
MX2010003329A (es)	2007-09-26	2010-04-27	Chugai Pharmaceutical Co Ltd	Anticuerpo anti-receptor de il-6.
EP3689912A1 (en) *	2007-09-26	2020-08-05	Chugai Seiyaku Kabushiki Kaisha	Method of modifying isoelectric point of antibody via amino acid substitution in cdr
KR102057826B1 (ko) *	2008-04-11	2019-12-20	추가이 세이야쿠 가부시키가이샤	복수 분자의 항원에 반복 결합하는 항원 결합 분자
EP2294087B1 (en)	2008-05-01	2014-05-14	Amgen, Inc.	Anti-hepcidin antibodies and methods of use
TWI440469B (zh)	2008-09-26	2014-06-11	Chugai Pharmaceutical Co Ltd	Improved antibody molecules

2003
- 2003-10-10 AU AU2003271174A patent/AU2003271174A1/en not_active Abandoned
- 2003-10-10 WO PCT/JP2003/013062 patent/WO2005035753A1/ja not_active Ceased
2004
- 2004-10-07 TW TW093130368A patent/TW200514790A/zh not_active IP Right Cessation
- 2004-10-08 BR BRPI0415230-1A patent/BRPI0415230B1/pt not_active IP Right Cessation
- 2004-10-08 DK DK04792180.4T patent/DK1688488T3/da active
- 2004-10-08 ES ES04792180T patent/ES2370250T3/es not_active Expired - Lifetime
- 2004-10-08 EP EP04792180A patent/EP1688488B9/en not_active Expired - Lifetime
- 2004-10-08 EP EP10180356A patent/EP2289944A3/en not_active Withdrawn
- 2004-10-08 PL PL16162353T patent/PL3085783T3/pl unknown
- 2004-10-08 AT AT04792180T patent/ATE518952T1/de not_active IP Right Cessation
- 2004-10-08 CA CA2541671A patent/CA2541671C/en not_active Expired - Lifetime
- 2004-10-08 AU AU2004280421A patent/AU2004280421B2/en not_active Expired
- 2004-10-08 DK DK16162353.3T patent/DK3085783T3/da active
- 2004-10-08 US US10/575,193 patent/US8062635B2/en active Active
- 2004-10-08 SI SI200432510T patent/SI3085783T1/sl unknown
- 2004-10-08 WO PCT/JP2004/014911 patent/WO2005035756A1/ja not_active Ceased
- 2004-10-08 KR KR1020127033128A patent/KR101361437B1/ko not_active Expired - Lifetime
- 2004-10-08 CN CN200480036248.8A patent/CN1890369B/zh not_active Expired - Lifetime
- 2004-10-08 EP EP16162353.3A patent/EP3085783B1/en not_active Expired - Lifetime
- 2004-10-08 MX MXPA06003831A patent/MXPA06003831A/es active IP Right Grant
- 2004-10-08 UA UAA200604899A patent/UA95438C2/ru unknown
- 2004-10-08 NZ NZ546509A patent/NZ546509A/en not_active IP Right Cessation
- 2004-10-08 NO NO20160762A patent/NO345624B1/no unknown
- 2004-10-08 RU RU2006115614/13A patent/RU2339696C2/ru active
2006
- 2006-04-05 IL IL174794A patent/IL174794A/en active IP Right Grant
- 2006-05-08 KR KR1020067008860A patent/KR101471194B1/ko not_active Expired - Lifetime
- 2006-05-09 NO NO20062087A patent/NO338686B1/no unknown

Also Published As

Publication number	Publication date
DK1688488T3 (da)	2011-09-26
PL3085783T3 (pl)	2021-07-19
UA95438C2 (ru)	2011-08-10
KR20060111497A (ko)	2006-10-27
TWI354676B (da)	2011-12-21
CN1890369B (zh)	2017-07-28
BRPI0415230A (pt)	2006-12-12
NO20062087L (no)	2006-07-07
SI3085783T1 (sl)	2021-07-30
EP1688488A1 (en)	2006-08-09
EP3085783B1 (en)	2021-01-27
AU2004280421B2 (en)	2011-06-02
RU2339696C2 (ru)	2008-11-27
TW200514790A (en)	2005-05-01
ATE518952T1 (de)	2011-08-15
RU2006115614A (ru)	2007-11-20
CA2541671C (en)	2015-01-06
KR101361437B1 (ko)	2014-02-11
AU2003271174A1 (en)	2005-04-27
US8062635B2 (en)	2011-11-22
EP1688488B9 (en)	2012-03-21
ES2370250T3 (es)	2011-12-13
KR20130018932A (ko)	2013-02-25
AU2004280421A1 (en)	2005-04-21
EP1688488A4 (en)	2008-03-05
US20070041978A1 (en)	2007-02-22
IL174794A0 (en)	2006-08-20
CN1890369A (zh)	2007-01-03
NO338686B1 (no)	2016-09-26
EP2289944A2 (en)	2011-03-02
NZ546509A (en)	2010-03-26
EP2289944A3 (en)	2011-03-09
IL174794A (en)	2011-11-30
EP3085783A1 (en)	2016-10-26
NO20160762A1 (no)	2006-07-07
WO2005035753A1 (ja)	2005-04-21
CA2541671A1 (en)	2005-04-21
BRPI0415230B1 (pt)	2023-01-10
NO345624B1 (no)	2021-05-18
WO2005035756A1 (ja)	2005-04-21
MXPA06003831A (es)	2006-07-03
KR101471194B1 (ko)	2014-12-09
EP1688488B1 (en)	2011-08-03

Publication	Publication Date	Title
DK3085783T3 (da)	2021-04-26	Bispecifikt antistof som substitution for funktionelle proteiner
DE602004025101D1 (de)	2010-03-04	Humane anti-humane cd3-bindungsmoleküle
CY1119416T1 (el)	2018-03-07	Αντισωματα εναντι των τοξινων toy clostridium difficile (κλωστηριδιο το δυσκολο) και χρησεις εξ' αυτων
MY163480A (en)	2017-09-15	Sclerostin binding agents
DK1434791T3 (da)	2010-02-15	Specifikke bindingsmidler til human angiopoietin-2
WO2006118772A3 (en)	2007-05-31	Fcrn antibodies and uses thereof
WO2006076594A3 (en)	2007-04-19	Antibodies and fc fusion proteins with altered immunogenicity
DK1626985T3 (da)	2011-06-14	Generering af kunstige bindingsproteiner på basis af ubiquitin proteiner
DK2316852T3 (da)	2014-06-16	Stabiliserede enkeltdomæne-antistoffer
EA200801621A1 (ru)	2008-12-30	Антитела, направленные на her-3, и их применение
WO2004099249A3 (en)	2006-01-26	Optimized fc variants and methods for their generation
MY174493A (en)	2020-04-23	Binding agents
EA200801172A1 (ru)	2008-12-30	Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения
WO2005017205A3 (en)	2005-03-31	Nucleic acid mapping using linear analysis
TW200606177A (en)	2006-02-16	Glycoprotein VI antibodies and methods thereof
WO2004094476A3 (en)	2005-06-16	Compositions and methods relating to stop-1
WO2004069860A3 (en)	2005-03-24	Isg15-conjugated proteins
DK1208213T3 (da)	2004-11-01	Fremgangsmåde til fremstilling af proteiner i værtsceller under anvendelse af chaperoniner
WO2006136892A3 (de)	2007-08-23	Neuartige cherlasky - fusionsproteine enthalten antikorperbindeproteine oder ihre regionen
EA200701031A1 (ru)	2007-10-26	Молекулы, способствующие гематопоэзу